Journal of Obesity & Weight Loss Therapy
Open Access

Abstract

Dysfunction of adipose tissue in obesity may play an important role in the development of the obesity-associated cardiometabolic disturbances, resulting in insulin resistance, type 2 diabetes, hypertension, lipid and lipoprotein disorders, and vascular, atherosclerotic disease. The treatment of cardiometabolic risk should include weight reduction, increased physical activity and lifestyle changes followed by pharmacotherapy to treat each risk factor individually. The important role of adipose tissue derived cytokines and adipokines in the development of cardiometabolic disturbances may point out an interest to improve adipose tissue function. Substantial evidence indicates that pharmacological treatments and nonpharmacological interventions affect adipose tissue function. Weight loss and increasing physical activity are effective interventions for improving adipose tissue function: weight reduction resulting in a decrease leptin and an increase in adiponectin levels. Treatment with orlistat is associated with decreased plasma concentrations of leptin, CRP, IL-6, TNF-�?±, resistin and increased adiponectin levels, indicating an improvement in adipose tissue function. Metformin has a direct effect on adipose tissue production, beyond an effect through weight reduction. Some drugs widely used in the treatment cardiometabolic risk mediate their cardiovascular benefits partly through their direct positive effects on adipocytes production besides primary therapeutical end points. Adiponectin levels are increased by statins, angiotensin converting enzyme inhibitors, and thiazolidinediones. The goal of obesity treatment is to reduce body weight, cardiometabolic risk, and improve adipose tissue function, which can be done with a combination of pharmacological treatments and non-pharmacological interventions. Improving adipose tissue function may play an important role in reducing the risk of cardiovascular diseases and the development of insulin resistance and type 2 diabetes.

Biography

Edita Stoki�?�? endocrinologist, Professor of Internal medicine-Endocrinology, employed in the Clinic of Endocrinology, Diabetes and Metabolic Disorders of the Clinical Centre of Vojvodina in Novi Sad, Medical Facukty, Serbia. In 2005. she was appointed as Chief of Department. She is currently the Vice President of Serbian Association for the Study of Obesity and Chairman of the Continuing Education Board (Society of Physicians of Vojvodina of the Medical Society of Serbia). She was President of the Internal Medicine Section and President of Endocrinology Section within same Society. Edita Stoki�?�? is an author or co-author of 412 scientific articles, and publications on obesity, dyslipidemias and diabetes. She has also published monographs - Obesity is a treatable disease and Obesity and adipose tissue distribution – metabolic consequences.

Email: edith@sezampro.rs